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novel elvitegravir nanoformulation 
for drug delivery across the 
blood-brain barrier to achieve 
HIV-1 suppression in the CNS 
macrophages
Yuqing Gong  1, pallabita chowdhury1, prashanth K. B. nagesh5, Mohammad A. Rahman3, 
Kaining Zhi  4, Murali M. Yallapu1,2* & Santosh Kumar1*
The use of antiretroviral therapy (ART) has remarkably decreased the morbidity associated with 
HIV-1 infection, however, the prevalence of HIV-1-associated neurocognitive disorders (HAND) is still 
increasing. The blood-brain barrier (BBB) is the major impediment for penetration of antiretroviral 
drugs, causing therapeutics to reach only suboptimal level to the brain. Conventional antiretroviral 
drug regimens are not sufficient to improve the treatment outcomes of HAND. In our recent report, 
we have developed a poloxamer-PLGA nanoformulation loaded with elvitegravir (EVG), a commonly 
used antiretroviral drug. The nanoformulated EVG is capable of elevating intracellular drug uptake and 
simultaneously enhance viral suppression in HIV-1-infected macrophages. In this work, we identified 
the clinical parameters including stability, biocompatibility, protein corona, cellular internalization 
pathway of EVG nanoformulation for its potential clinical translation. We further assessed the ability 
of this eVG nanoformulation to cross the in vitro BBB model and suppress the HIV-1 in macrophage 
cells. Compared with EVG native drug, our EVG nanoformulation demonstrated an improved BBB 
model penetration cross the in vitro BBB model and an enhanced HIV-1 suppression in HIV-1-infected 
human monocyte-derived macrophages after crossing the BBB model without altering the BBB model 
integrity. Overall, this is an innovative and optimized treatment strategy that has a potential for 
therapeutic interventions in reducing HAND.
In the past two decades, the introduction of antiretroviral therapy (ART) has made significant advances in man-
aging HIV-1/AIDS effectively1. However, the prevalence of HIV-1-associated neurocognitive disorders (HAND) 
is still a major concern, especially in the aging population2. The appearance and persistence of HAND are partially 
due to the entry of HIV-1-infected monocytes into the brain3. Within the CNS, HIV-1-infected monocytes dif-
ferentiate into macrophages, which produce virus and spread the virus into the brain, leading to HAND4. HIV-
1-infected macrophages serve as one of the major viral reservoirs in the CNS, provide active viral replication, even 
when systemic viral suppression has been achieved by ART5. An efficient viral suppression on CNS macrophages 
is important for an effective HIV-1 treatment in the brain.
The hindrance in the treatment of HAND is mainly contributed by the inability of antiretrovirals (ARVs) to 
cross the blood-brain barrier (BBB) after the systemic administration6. Previous clinical studies demonstrate 
that the central nervous system (CNS) Penetration-Effectiveness (CPE) of ARVs is correlated with the inhibi-
tion of HIV-1 replication in the CNS and cognitive performance in HIV-1 positive patients7,8. However, con-
ventional regimens of ARVs are not sufficient to improve the penetration of ARVs and the outcomes in HAND9. 
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Approximately 25% of the patients developed one or more neurological syndromes, despite receiving ART10. 
Several approaches have been employed to improve the penetration of ARVs, including ATP-binding cassette 
(ABC) transporters blocking method, BBB opening strategy, prodrug therapy, and nanoparticle-based drug deliv-
ery11. Blocking of ABC transporters may cause serious drug-drug interactions due to the abundant presence of 
ABC transporters in other organs. Opening the tight junctions of the BBB is not recommended because it may 
also allow the entry of virus and other contaminants into the brain. United States Food and Drug Administration 
(FDA) approval for prodrugs is complicated and difficult because prodrugs are considered as a separate chemical 
entity than the parent molecule11. Compared with other CNS delivery approaches, nanoparticle-based drug deliv-
ery approach is an attractive option for the treatment of HAND12.
Nanoparticle-based drug delivery system provides a relatively safe profile, protects ARVs from efflux trans-
porters as well as from enzymatic and hydrolytic degradations, and can be used for a sustained-release of ther-
apeutics9. Nanoparticles (NPs) that have been studied for brain delivery mainly include polymeric NPs such as 
poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(D, L-lactide-co-glycolide) (PLGA), and poly(butylcy-
anoacrylate) (PBCA) NPs13,14, and metal-based NPs such as gold, silver, and zinc oxide NPs14. Since polymeric 
NPs are not only easy to be prepared and stored but highly biocompatible and biodegradable in nature, polymeric 
NPs have been extensively studied for delivery of therapeutics for cancer15–18 and HIV-119–22. However, the use of 
polymeric NPs to deliver ARVs to the brain for the treatment of HAND is still underdeveloped.
In this study, a commonly used ARV, elvitegravir (EVG), was formulated into a poloxamer- PLGA nano-
particle (PLGA NPs). In our recent report, we have successfully encapsulated EVG into poloxamer-PLGA 
NPs (PLGA-EVG NPs), which improved intracellular uptake of EVG in monocyte-derived macrophages and 
viral suppression in HIV-1-infected primary macrophages23. To utilize PLGA NPs as a potential tool for drug 
delivery to the brain, in this work, we studied the clinically relevant properties for drug delivery applications 
of these PLGA NPs such as stability and the safety profile. We also identified the interaction of human serum 
(HS) proteins and PLGA NPs, and the safety profile of the HS-PLGA NP complex that includes their hemo- and 
cyto-compatibility. Further, we performed the transmigration study of PLGA NPs in the in vitro BBB model, 
and subsequently assessed the efficacy of PLGA-EVG NPs on viral suppression of HIV-1-infected primary mac-
rophages after crossing the BBB model. Overall, PLGA NPs provided a promising delivery of EVG across the BBB 
model and has a potential for therapeutic interventions in reducing HAND.
Results
formulation design and in vitro release of PLGA-EVG NPs. The PLGA-EVG NP formulation in our 
study is an oil-in-water (o/w) emulsion. A hypothetical structure of PLGA-EVG NP is described in Fig. 1A. PLGA 
was the main polymer core to hold EVG molecules, PVA was used to stabilize the emulsion; poloxamer 188 was 
used as a stabilizer and to provide a better brain penetration; PLL was used to provide slightly positive charge, 
which helps internalize into the cells. The in vitro release of PLGA-EVG NPs in cell culture media is shown in 
Fig. 1B. The release of EVG from PLGA NPs followed a zero-order release profile with r2 of 0.98 within 24 h. Only 
~15% of cumulative EVG release was observed at 24 h, which suggested the potential controlled release profile of 
PLGA-EVG NPs. The drug release from PLGA NPs may be related to the drug/PLGA loading ratio, NP protected 
layer stability, and physicochemical properties of EVG.
Size and zeta potential of PLGA NPs. The size of freshly made PLGA NPs was approximately 135.7 ± 
1.5 nm in PBS (Table 1). No specific change in particle size and zeta potential of NPs was observed for 7 days when 
stored at room temperature. PLGA NPs can be stored at 4 °C and −20 °C for at least 30 days with no change on 
size and zeta potential. PLGA NPs showed a stable particle size in 1 mM HEPES buffer within the pH range of 
1–11 (Table 2). PLGA NPs showed a positive charge (~7 mV) at all the recorded pH values except pH 4, 5, and 
11. A higher positive charge (~20 mV) of PLGA NPs was observed at the pH range of 4–5, and a lower charge 
(~3 mV) of PLGA NPs was observed at pH 11.
Figure 1. Formulation design and in vitro release of PLGA-EVG NPs. (A) A hypothetical structural 
representation of PLGA-EVG NP (B) In vitro release profile of PLGA-EVG NPs. Mean ± SEM values were 
graphed from 3 independent experiments.
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Evaluation of human serum protein binding on PLGA NPs. It is expected that HS protein binding 
occurs when NPs are taken by human body24. Upon introduction of NPs into the body, NPs dynamically interact 
with all the serum proteins and form the NP-protein complex25. Understanding the interaction of NPs with HS 
can predict their safety and efficacy profiles when used in the clinic24. Therefore, a DLS assay of PLGA NPs was 
investigated in PBS and 1–50% HS. A slight increase in particle size was observed for PLGA NPs in 1–50% HS 
(Fig. 2A). HS proteins are loosely bound to the PLGA NPs, leading to this slight increase in particle size. Zeta 
potential of PLGA NPs was observed to be negative in 1–50% HS (Fig. 2B). This negative charge is expected, 
because HS is negatively charged in pH 7.4 PBS. The negative zeta potential indicates that PLGA NPs are stable 
and safe for therapeutic applications. PLGA NPs did not precipitate in the presence of HS. To confirm the human 
serum binding on PLGA NPs, we performed a FTIR analysis of PLGA NPs, HS, and HS@NPs. The FTIR data was 
presented from 600 to 1800 cm−1 to observe the HS protein peaks. The peaks at 1661 cm−1 and 1541 cm−1 was 
found in HS and HS@NPs due to the amide bond stretch of the HS protein. The peak extent of the HS proteins 
in HS@NPs showed a concentration dependent increase at increasing percentage of HS (Fig. 2C). Moreover, we 
further confirmed the PLGA NPs-protein interaction using SDS-PAGE analysis, in which, it can be observed the 
HS proteins binding on HS@NPs. The identified major proteins that bind on NPs are: transferrin, human serum 
albumin (HSA), fibrinogen beta, fibrinogen gamma, apolipoprotein E (Apo E), and apolipoprotein A1 (Apo A1) 
according to the molecular weight26. We found that HS proteins were adsorbed to the surface of PLGA NPs when 
the concentration of HS increased (Fig. 2D). With an increased incubation time, an increased protein binding on 
the PLGA NPs was observed (Fig. 2E). HS protein binding also showed an increased pattern when the amount of 
PLGA NPs was increased up to 180 µg while HS protein binding decreased when incubated with more than 180 µg 
of NPs (Fig. 2F). This indicates the saturation of binding with NPs due to the limited HS amount and incubation 
time.
Hemocompatibility of PLGA NPs. Hemocompatibility tests evaluate the effects on RBCs when introduce 
a foreign compound to the blood. Both visual inspection (Fig. 3A) and spectrophotometric measurement of 
hemoglobin release (Fig. 3B) suggested that PLGA NPs do not cause hemolysis even at the highest concentration 
(200 µM) that was used in the assay. A dose dependent hemolysis was observed in RBCs treated with EVG native 
drug. At the highest tested concentration (200 µM), EVG native drug caused ~30% hemolysis while PLGA-EVG 
NPs did not cause hemolysis. Similarly, HS30@EVG NPs also caused low hemolysis (~4%) compared to EVG 
native drug (~30%). Moreover, EVG native drug caused morphology change on RBCs, while PLGA-EVG NPs 
and HS30@EVG NPs caused no change on the RBC morphology (Fig. 3C). The hemocompatibility of PLGA NPs 
could be because of the biocompatibility of the polymer and the HS adsorption on the PLGA NPs.
Toxicity evaluation of PLGA-EVG NPs in monocytes-derived macrophages (MDM). It is impor-
tant to carefully control the biocompatibility and cytotoxicity of a biomaterial for the potential use in the clinic27. 
Thus, we evaluated the toxicity profile of PLGA-EVG NPs with monocytes-derived macrophages (MDM). Over 
the range of 0–20 µM EVG, PLGA-EVG or 30HS@EVG NPs, ~100% cell viability was observed with all these 
groups when compared to control cells (Fig. 4A). No change in cell morphology was observed even after treating 
with the highest concentration (20 µM) of EVG free drug/PLGA-EVG NPs/HS30@PLGA-EVG (Fig. 4B).
Internalization mechanism of the PLGA NPs in MDM. In our recent report, we showed a time- and 
concentration-dependent uptakes of PLGA NPs in monocytes23. To further study the endocytosis pathways of 
these PLGA NPs in macrophage, various endocytosis inhibitors were utilized. The inhibitors include nocodazole, 
Cyto-D, CPZ, monensin, genistein, and MβCD, which suppress microtubule-related internalization, macropi-
nocytosis, clathrin-mediated endocytosis, lysosome-involved internalization, caveolae-mediated pathways, and 
caveolae-/clathrin-mediated endocytosis, respectively28,29. To detect by flow cytometry, a fluorescence probe, C6 
Days
Room temperature 4 °C −20 °C
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 7 Day 30 Day 7 Day 30
Size (nm) 135.7 ± 1.5 134.4 ± 0.7 135.5 ± 0.5 135.7 ± 0.4 132.6 ± 0.6 134.2 ± 1.3 135.9 ± 1.4 134.6 ± 1.2 132.1 ± 0.5 133.1 ± 0.5 131.9 ± 0.2 132.9 ± 0.3
Zeta 
potential 
(mV)
0.11 ± 0.5 −0.53 ± 0.3 −0.18 ± 0.3 −0.02 ± 0.18 0.62 ± 0.2 −0.37 ± 0.2 0.00 ± 0.2 −0.18 ± 0.3 −0.25 ± 0.2 −0.22 ± 0.3 −0.02 ± 0.3 −0.12 ± 0.3
Table 1. Size and zeta potential of PLGA NPs stored at room temperature, 4 °C, and −20 °C. Mean ± SEM 
values were calculated from three measurements. Size and zeta potential of NPs from different storage 
conditions were compared with day 0, room temperature sample.
pH 1 pH 3 pH 4 pH 5 pH 6 pH 7.4 pH 8 pH 10 pH 11
Size (nm) 132.2 ± 1.0 132.5 ± 0.8 134.4 ± 0.8 133.8 ± 0.9 132.1 ± 0.4 132.0 ± 0.4 131.5 ± 1.2 126.9 ± 0.7 128.3 ± 1.5
Zeta 
potential 
(mV)
7.02 ± 0.2 6.36 ± 0.6 18.87 ± 1.8 22.27 ± 0.4 7.72 ± 1.3 7.94 ± 0.75 6.90 ± 0.55 5.87 ± 0.34 3.40 ± 0.31
Table 2. Size and zeta potential of PLGA NPs in 1 mM HEPES buffer from pH 1 to pH 11. Mean ± SEM values 
were calculated from three measurements.
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(green) was encapsulated in PLGA NPs. The inhibition effect of all the endocytosis inhibitors on the internaliza-
tion of PLGA-C6 NPs in MDM are minor, indicating that the internalization of PLGA NPs in MDM may relate to 
a combination of endocytosis pathways (Fig. 5A,B). We further examined the sub-cellular fate of PLGA NPs using 
a confocal microscopic analysis (Fig. 5C). PLGA NPs were efficiently internalized in MDM after 2.5 h exposure. A 
co-localization of PLGA-C6 and early endosome marker were observed, but less co-localization was observed in 
the presence of late-endosomal marker, and no co-localization was observed in the presence of the lysosomal and 
mitochondria marker. This suggests that PLGA NPs can escape from endo-lysosomal compartments and deliver 
the therapeutics to the macrophages efficiently.
In vitro BBB model and teeR assessments. The in vitro BBB model used in this study was co-cultured 
endothelial cells (bEnd.3) with astrocytes (C8-D1A) in a Transwell® plate as described in the method section 
(Fig. 6A). The bEnd.3 cell are a commercially available cell line and a useful BBB-mimicking system for biological 
and pharmacological research because it expresses efflux transporters P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP)30,31. A bEnd.3/C8-D1A co-culture model has shown to present significantly higher 
tight junctions than the monoculture of bEnd.332. In our study, TEER values were measured for 6 days after 
co-culturing. We observed that the TEER value reached a plateau on day-4 and it was stable from 4 to 6 days 
(Fig. 6B). A mean TEER value of 100 to 120 Ohms × cm2 was observed in the confluent BBB model, which is 
consistent with the literature report32. All transmigration experiments were conducted after membrane integrity 
was stable with consistent TEER values.
Transmigration of PLGA-C6 NPs across the in vitro BBB model. The characterization of the 
PLGA-C6 NPs was reported previously, which demonstrated a time- and dose-dependent uptakes in mono-
cytes23. To test the transmigration of PLGA-C6 NPs across the in vitro BBB model, three different concentrations 
of PLGA-C6 NPs were exposed in the upper chamber, and the culture media in the bottom chamber was col-
lected after 24 hours. The penetration of PLGA-C6 NPs was examined by quantifying the fluorescence intensity 
Figure 2. Evaluation of human serum protein binding on PLGA NPs. (A) Particle size of PLGA NPs in 1–50% 
human serum. (B) Zeta potential of PLGA NPs in 1–50% human serum. (C) FTIR spectra of human serum, 
PLGA NPs and HS@NPs. (D,E) SDS-PAGE of adsorbed human serum proteins on PLGA NPs. Data represents 
human serum proteins bind to PLGA NPs depending on the (D) concentration of human serum, (E) incubation 
time, and (F) concentration of PLGA NPs. Mean ± SEM values are from 3 independent experiments.
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of the culture media, which was collected from the bottom chamber. We observed a dose-dependent increase 
in fluorescence intensity from media samples, which suggests a dose-dependent penetration of PLGA-C6 NPs 
across the BBB model (Fig. 7A). This finding is also supported by a quantification of C6 from the same media. 
C6 concentrations of the media collected from the bottom chamber were calculated using a C6 calibration curve. 
The penetration of C6 across the BBB model also followed a dose-dependent profile, and all the PLGA-C6 groups 
showed significant increase in C6 fluorescence intensity compared with PLGA-Blank after crossing the BBB 
model (Fig. 7B, *p < 0.05 compared with PLGA-Blank, #p < 0.05 compared with the previous concentration). 
These results were also validated by the qualitative imaging of recipient astrocytes, which showed that PLGA-C6 
NPs were taken up by cells in a dose-dependent manner after crossing the BBB model. The highest fluorescence 
was observed in cells treated with the highest concentration of PLGA-C6 NPs (Fig. 7C).
Increased penetration of PLGA-EVG NPs in the in vitro BBB model. To understand whether nan-
oparticle formulation can increase the transmigration of EVG in the in vitro BBB model, we measured EVG 
amount in the bottom chamber from both media and cell lysate samples. As expected, PLGA-EVG NPs showed 
higher penetration compared to EVG native drug. A dose-dependent penetration profiles for both EVG native 
drug and PLGA-EVG NPs were observed. A significant increase of EVG penetration was observed for both free 
EVG and PLGA-EVG NPs from 2.5 µg/mL to 5 µg/mL and from 5 µg/mL to 10 µg/mL (Fig. 8A, *p < 0.05 com-
pared with PLGA-Blank, #p < 0.05 compared with the previous concentration). The results showed that a max-
imum of 27% of PLGA-EVG NPs can cross the BBB model after 24 hours. The results also showed a significant 
increase in penetration of PLGA-EVG NPs compared to EVG native drug at the dose of 5 µg/mL and 10 µg/mL. 
We also performed a time-dependent penetration study using 5 µg/mL of native EVG/PLGA-EVG NPs. Both 
Figure 3. Hemocompatibility of PLGA NPs. (A) Visual inspection of the tubes containing RBCs after exposure 
to 5–200 µM EVG, EVG NPs, HS30@EVG NPs, Blank NPs, and HS30@Blank NPs. (B) Hemolysis of RBCs 
upon incubation with 5–200 µM EVG, EVG NPs, HS30@EVG NPs, Blank NPs, and HS30@Blank NPs. (C) 
Microscopic images of RBCs treated with 200 µM EVG, EVG NPs, HS30@EVG NPs, Blank NPs, and HS30@
Blank NPs. 1X PBS was used as negative control, water was used as positive control #1, and sodium dodecyl 
sulfate (SDS) was used as positive control #2. % of hemolysis was calculated based on the positive control #1. 
Data represents triplicates.
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Figure 4. Toxicity evaluation of PLGA-EVG NPs in MDM. (A) Cell viability of MDM with the treatment of 
0–20 µM EVG, PLGA-EVG NPs, and 30% human serum-PLGA-EVG NPs complex (HS30@PLGA-EVG) from 
XTT assay. (C) Microscopic images of MDM with the treatment of 0 and 20 µM EVG, PLGA-EVG NPs, and 
HS30@PLGA-EVG. 5% acetonitrile was used as a positive control. Mean ± SEM values are from 5 replicates.
Figure 5. Internalization mechanism of the PLGA-C6 NPs in MDM. (A) Cellular uptake of PLGA-C6 NPs. 
in the presence of various endocytosis inhibitors. Bar equals to 5 µm in confocal images. (B) Relative cellular 
uptake percentage calculated from the mean fluorescence intensity measured by flow cytometry in MDM. 
Mean ± SEM are from 3 measurements. *p < 0.05. (C) Co-localization evaluation of PLGA-C6 NPs (green) in 
presence of markers (red) for early endosome, late endosome, lysosome, and mitochondria. DAPI was used to 
stain nuclei (blue). White arrow indicates the co-localization of PLGA-C6 NPs with early- and late- endosome 
markers in the cells. Cells were visualized under 400× magnification (Bar = 5 µm).
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native drug and NPs showed a time-dependent penetration across the BBB model. Penetration of PLGA-EVG 
NPs across the BBB model showed a significant increase in the area under the curve (AUC) compared to EVG 
native drug (Fig. 8B, *p < 0.05). These results demonstrate that PLGA-EVG NPs improve the ability of EVG to 
cross the BBB model in the in vitro model. Moreover, no changes were observed for TEER values (Fig. 8C) and 
endothelial cell morphology (Fig. 8D) before and after the treatment, suggesting that PLGA-EVG transmigration 
did not change the monolayer integrity of the BBB model. Additionally, we identified the mechanistic contribu-
tion of P-gp in interfering the penetration of EVG in the in vitro BBB model and the capability of PLGA NPs to 
bypass the BBB efflux transportation. For this, we performed a penetration study in the presence and absence of a 
P-gp inhibitor elacridar for 24 hours (Fig. 8E). The AUC(0-t) of in vitro BBB penetration for EVG was significantly 
increased in the presence of the P-gp inhibitor, suggesting that the low EVG level in the CNS is, at least in part, 
mediated by P-gp efflux transportation (Fig. 8F). In contrast, the penetration of PLGA-EVG NPs showed no 
change in the presence and absence of the P-gp inhibitor, suggesting the ability of NP to bypass the efflux trans-
porter P-gp in the in vitro BBB.
Figure 6. In vitro BBB model. (A) Graphical representation of the in vitro BBB model. (B) TEER measurements 
were obtained by applying a transendothelial current to the membrane and then testing the resistance (current, 
Ohm) multiplied by the area (cm2) of the endothelial monolayer (Ohm⋅cm2) by using EVOM2 meter. (C). Mean 
± SEM values were graphed from 3 independent experiments.
Figure 7. Dose dependent penetration of PLGA NPs across the BBB in vitro. (A) Quantitative penetration of 
PLGA-C6 after 24 hours exposure of PLGA-C6 to the top insert. The florescence intensities of the media from 
bottom chambers was determined by SpectraMax M2e UV spectrometer. Fluorescence was studied by exciting 
at 488 nm and emission between 400–650 nm. (B) C6 concentration in the media was calculated using a C6 
calibration curve with the matrix of media. C6 concentration of 1 µg/mL represents 302101 mean florescence 
intensity (area under the curve). (C) Bright field, fluorescent, and overlay images of astrocytes from bottom 
chambers after 24 hours exposure of PLGA-C6 to the top insert. PLGA-C6 was taken up dose-dependently by 
the astrocytes in bottom chambers after crossing the BBB. The green florescence was visualized using an EVOS® 
FL Imaging System. Scale bar = 200 µm. Mean ± SEM values were graphed from 3 measurements. *Indicate 
p < 0.05 compared with PLGA-Blank, #Indicate p < 0.05 compared with the previous concentration.
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Improved viral suppression in HIV-1-infected MDM after crossing the in vitro BBB model. Since 
macrophages can be infected productively by HIV-1 in the CNS33, we examined the viral suppression efficacy of 
PLGA-EVG NPs in HIV-1-infected macrophages. We examined PLGA-EVG NPs and native EVG for their effects 
Figure 8. Dose-/time-dependent penetration of EVG and PLGA-EVG NPs across the BBB in vitro. (A) Dose 
dependent penetration profile of EVG/PLGA-EVG NPs across the BBB in vitro. Mean ± SEM values were 
graphed from 3 independent experiments. *Indicate p < 0.05 compared with native EVG drug, # indicate 
p < 0.05 compared with the previous EVG/PLGA-EVG concentrations. (B) Time dependent penetration profile 
of EVG/PLGA-EVG NPs across the in vitro BBB. Quantitative penetration of EVG was determined by LC-MS/
MS. Mean ± SEM values were graphed from 3 independent experiments. *Indicate p < 0.05 compared with 
native EVG drug, (C) Trans endothelial electrical resistance (TEER) of the endothelial cell layer was measured 
before and after treatment. (D) Microscopic images of the endothelial cells from the top insert were taken 
before and after treatment using an EVOS® FL Imaging System. Scale bar = 200 µm. Mean ± SEM values were 
graphed from 3 independent experiments. (E) Time course penetration profile of EVG/PLGA EVG NPs across 
the in vitro BBB in presence and absence of P-gp inhibitor elacridar. (F) Area under the curve of EVG and 
PLGA-EVG penetration in presence and absence of P-gp inhibitor elacridar. Area under the curve from 0 to last 
time t (AUC0–t) was calculated using the linear trapezoidal method. Mean ± SEM values were graphed from 3 
independent experiments. *Indicate p < 0.05 compared with native EVG drug in absence of P-gp inhibitor.
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on viral replication on HIV-1-infected MDM in a modified in vitro BBB model following a one-month treatment 
paradigm as described in the treatment scheme (Fig. 9A). HIV-1-infected MDM were cultured on the bottom 
chamber, which will not be exposed to EVG directly. Blank PLGA NPs, EVG, and PLGA-EVG NPs were given 
on the upper chamber, which contains BBB monolayer. TEER values of the BBB model were measured for all the 
groups every day. Both EVG and PLGA-EVG NPs did not compromise the physiological integrity of the in vitro 
BBB model (Fig. 9B). HIV p24 protein level was measured from the bottom chamber daily. The effect of viral 
suppression in the MDM will be caused by the EVG/PLGA-EVG upon crossing the BBB monolayer to the bottom 
chamber. Our results showed that PLGA-Blank NPs have no effect on viral replication. However, both native EVG 
and PLGA-EVG NPs suppressed the viral replication to 70–100% of control (Fig. 9C). We calculated the p24 area 
under the curve (AUC) to compare the viral suppression efficacy of native EVG and PLGA-EVG NPs from day-1 
to day-7 (Fig. 9D, *p < 0.5). The results showed that the HIV-1-infected MDM, when exposed to PLGA-EVG NPs 
have a significantly lower viral load, indicating that PLGA-EVG NPs have better efficacy on viral suppression in 
HIV-1-infected MDM after crossing the in vitro BBB model. We also measured EVG levels in MDM at the end of 
the treatment. EVG levels in MDM was significantly increased when exposed to PLGA-EVG NPs, compared with 
EVG native drug (Fig. 9F, *p < 0.5). This result suggests that the enhanced viral suppression efficacy, achieved by 
PLGA-EVG NPs, is correlated with increased EVG intracellular uptake in MDM.
Discussion
Although HIV-1-associated dementia (HAD), the most severe form of HAND, is rare in developed countries34, 
there is no specific treatment option available for HAND2. Currently, ART is the best option for delaying or pre-
venting HIV-1 disease progression35. However, due to the inability of ARVs to cross the BBB following systemic 
administration, ART is still not clinically applicable for the treatment of HAND2. HIV-1 infection in CNS cells 
affects not only cognitive functioning but also the opportunity of HIV-1 eradication2. Individuals with HAND 
commonly show characteristics of dysfunctional and impaired judgment, memory, multitasking, and attention36. 
The CNS can serve as a viral reservoir for production of HIV-1, and limit the opportunity for viral eradica-
tion37. Thus, there is a need for novel treatment regimens that cross the BBB and deliver therapeutic into the 
CNS to suppress the viral replication in the CNS cells, especially viral reservoirs. The Nair group has explored a 
field-controlled magnetic-NP drug formulation with the capability of magnetic field-triggered release across the 
BBB, for delivery of ARVs or siRNAs to the brain38–40. The same group has also collaborated with the El-Hage 
group and demonstrated an intranasal delivery of siRNA in mouse brain to achieve HIV-1 attenuation41. The 
Gendelman group also has extensive experience with ARV nanoformulation where they have developed several 
long-acting nanoformulated ARV prodrugs that show slow release profiles and improved antiretroviral activ-
ity42–44. Although these studies have demonstrated the use of nano-carriers to deliver ARVs to the brain38–41,45, 
none of these strategies are in clinic yet. Therefore, it is necessary to study and develop alternative, safe, and clin-
ically applicable ARV delivery systems for the treatment of HAND9,19.
We selected EVG as our model drug, which is a FDA-approved integrase strand transfer inhibitor, and is 
part of the first line ART regimen for the majority of HIV-1-infected populations in the USA46. EVG in this 
Figure 9. Viral suppression of EVG/PLGA-EVG in HIV-1-infected MDM after crossing in vitro BBB model. 
(A) Treatment paradigm for collecting HIV-1-infected MDM and performing EVG/PLGA-EVG viral 
suppression study. (B) TEER of the endothelial monolayer was measured at indicated time points. (C) Time 
course of HIV-1 replication upon drug exposure in HIV-1-infected MDM after crossing in vitro BBB model. All 
assays were performed on triplicate samples with MDM derived from two different donors. To minimize inter-
donor variability, p24 levels were normalized to the control MDM, which obtained from the same donor, and 
reported as a percentage of the control group. (D) Area under the curve of EVG and PLGA-EVG. Area under 
the curve from 0 to last time t (AUC0–t) was calculated using the linear trapezoidal method. (F) EVG levels in 
MDM at the end of the treatment. EVG levels in MDM were measured from the day-7 cell lysate samples from 
3 × 105 cells at the end of the experiment using LC-MS/MS. Mean ± SEM values were graphed from triplicate 
samples with MDM derived from two different donors. *Indicate p < 0.05 compared to EVG native drug.
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nanoformulation provides an effective antiretroviral ability and a favorable safety profile. In the last three years, 
researchers started formulating EVG into NPs to combat HIV-1 infection47,48. For example, EVG has been for-
mulated into a bioadhensive PLA NPs with a hyperbranched polyglycerols (HPG) coating on the surface47. These 
bioadhensive PLA NPs were distributed widely throughout the reproductive tract, and showed a prolonged 
intravaginal delivery of EVG. Moreover, EVG has been used together with tenofovir alafenamide (TFV) in a 
PLGA-based NPs coated with poloxamer 407 as a prevention strategy to against HIV-148. This EVG NPs can 
extend the t1/2 of EVG from 10.8 h to 3.3 days and protect mice with 100% and 60% uninfected rate on day 4 
and day 14 post-nanoparticle injection after a HIV-1 challenge. In contrast to the published EVG nanoparticle 
studies, our goal is to study the potential use of EVG NPs in CNS drug delivery to suppress the HIV-1 replication 
in the brain. Like other EVG NPs, we also developed a polymeric nanoparticle of EVG for a better stability and 
safety profile. An FDA-approved polymer, PLGA, was used to incorporate EVG and formulate the core of the NP. 
PLGA is a biocompatible polyester, which can be converted into water and carbon dioxide via tricarboxylic acid 
cycle and eventually eliminated from the body49. In addition, human body has shown to have low inflammatory 
response to PLGA suggesting its applicability for systemic administration clinically50. In this work, we identified 
that the safety and stability profile of the PLGA NPs, and both the safety and the stability profile of the PLGA NPs 
support their use as a potential CNS delivery strategy.
Understanding the mechanistic internalization of NPs by the targeted cells can increase our knowledge of 
how these particles are taken up and are transported within the cells, and to which extent they are secreted51. In 
general, most of the NPs are taken up into cells via endocytosis into endosomes and subsequently trafficked into 
lysosomal compartments52. Our data showed that a combination of different endocytosis pathways were involved 
in the uptake of PLGA NPs in the macrophages, which is consistent with previous studies53–55. Although initially 
present in early endosomes, PLGA NPs can still bypass the endo-lysosomal compartments in macrophages with 
less and no co-localization found in the presence of late endosome and lysosome marker, respectively. Our design 
allows the PLGA NPs escape the endo-lysosomal degradation/secretion, which helps the therapeutic to work 
effectively inside the cells52.
NPs have been demonstrated as a promising strategy to deliver drugs at the site of action, bypass transporters 
and drug metabolic enzymes, and cross the BBB19,21. Thus, we hypothesize that, EVG in PLGA NPs can bypass 
transporters on the BBB to perform a higher drug transmigration and can also bypass the transporters and drug 
metabolic enzymes on macrophages after crossing the BBB, showing improved viral suppression on the HIV-
1-infected macrophages. In order to have an efficient brain delivery, we used poloxamer 188 as the surfactant in 
our PLGA NP formulation. Poloxamer 188 is known to have low toxicity and able to decrease inflammation in 
the injured brain of experimental rats56. Poloxamer 188 has been used as an effective surfactant for brain deliv-
ery in cancer57,58. Literatures showed that poloxamer 188 coating can help PLGA NPs become to an efficient 
brain delivery method57. They demonstrated that poloxamer 188-coated PLGA NPs have a high anti-tumor effect 
against an intracranial 101/8 glioblastoma in rats, compared with the non-coated NPs. In another study, polox-
amer 188-coated PLGA NPs demonstrated the greatest cellular uptake in the brain tissues over the NPs coated 
with other commonly used surfactants such as polysorbate 80 and poloxamer 40758. Similarly, the poloxamer 
188-coated EVG NPs demonstrated an effective brain delivery profile in our study.
Currently, the magnetic nanoformulation is the most commonly studied nanoformulation for NeuroAIDS38,40. 
Magnetic NPs of azidothymidine showed a 3-fold higher transmigration in an in vitro BBB model, compared to 
the native drug38. This magnetic nanoformulation of azidothymidine also showed a slightly lower p24 antigen pro-
duction when treating with HIV-1-infected PBMCs. The same group also developed a magnetically layer-by-layer 
NPs with a ~37.95% BBB transmigration and ~33% p24 suppression on astrocytes in vitro40. Compared with those 
magnetic NPs, our PLGA-EVG NPs showed a comparable percentage of transmigration and an efficient viral sup-
pression in HIV-1-infected macrophages. To the best of our knowledge, this is the first report of using EVG nanofor-
mulation as a potential delivery method to cross the BBB model and suppress the HIV-1 in the CNS macrophages. 
We understand that the use of mouse model of the BBB with human macrophages is a limitation of this study. 
However, a combined model with mouse BBB cells and human macrophages fulfils the basic requirement for an 
in vitro BBB model that provides a comparison of both drug penetration and viral suppression of PLGA-EVG NPs 
and EVG native drugs in our study. In this model, the mouse BBB model can be used to study BBB transmigration 
because of the tight junction and the expression of efflux transporters P-gp and BCRP30–32. The validity of the BBB 
model in this study is further strengthen, because we are able to study the efficacy of the viral suppression in HIV-
1-infected human primary macrophages59. Overall, compare to commonly used magnetic NPs, our PLGA-EVG NPs 
is easy to prepare, is FDA-approved non-toxic NPs, and does not require an application of an external magnetic field. 
We expect that this PLGA-EVG NPs have the potential to move forward to the clinical use.
conclusion
Our current study demonstrated a poloxamer-PLGA based nanocarrier is an efficient delivery approach for EVG. 
The PLGA-EVG NPs demonstrated a favorable stability and safety profile. The PLGA-EVG NPs demonstrated 
significant transmigration across an in vitro BBB model. Most importantly, PLGA-EVG NPs showed an improved 
viral suppression in HIV-1-infected macrophages after crossing the BBB model. Ongoing study in our laboratory 
is to determine its safety and efficacy in animal model. This is the first step towards achieving our goal to create a 
safe and efficient drug delivery method to target HIV reservoirs in the CNS for potential clinical.
Material and Methods
Materials. Active ingredient elvitegravir (EVG, E509000) was purchased from Toronto Research Chemicals 
Inc. (Ontario, Canada). Poly(D,L-lactide-co-glycolide) (PLGA) (50:50 lactide-glycolide ratio, Mw: 31,000–50,000, 
ester-terminated) was brought from Birmingham Polymers (Pelham, AL). The following items were obtained 
from Sigma-Aldrich Co. (St. Louis, MO): poloxamer 188 (pluronic F-68) (P1300, Mw: 8350), poly(vinyl alcohol) 
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(PVA) (363138, Mw: 30,000–70,000), poly(L-lysine) (PLL) (Mw: 30,000–70,000), coumarin-6 (442631), acetone 
(650501), nocodazole (M1404), cytochalasin-D (Cyto-D) (C8273), chlorpromazine (CPZ) (C1240), monensin 
sodium salt (M5273), genistein (G6649), methyl-β-cyclodextrin (Mβ-CD) (C4555), hexadimethrine bromide 
(polybrene) (107689), MitoTrackerTM Deep Red (M22426), Texas RedTM Conjugate (T2875), and CellLightTM 
Late Endosomes-RFP (C10589). HPLC grade acetonitrile (A955) and formic acid (85178), BD PrecisionGlide 
25 G needle (14–826–49) and BD 1 mL TB syringe (14-826-88) were obtained from Fisher Scientific (Hampton, 
NH). Sterile phosphate-buffered saline was obtained from Gibco (Dublin, Ireland). Ethylenediaminetetraacetic 
acid (EDTA) was brought from Boston Bio Products (Ashland, MA).
The immortalized mouse brain endothelial cells (bEnd.3, CRL-2299) and mouse astrocytes (C8-D1A, CRL-
2541) were purchased from American Type Culture Collection (Manassas, VA, USA). Human monocytes-derived 
macrophages (MDM) were differentiated from the de-identified human blood, which was obtained from 
Interstate Blood Bank Inc. (Memphis, TN) upon approval from the Institutional Review Board (IRB, UTHSC). 
Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from American Type Culture Collection. Roswell 
Park Memorial Institute (RPMI) 1640 media and lymphocyte separation medium were bought from Corning Inc 
(Tewksbury, MA). Fetal bovine serum (FBS) was obtained from Atlanta biologicals (Atlanta, GA). L-glutamine 
and penicillin-streptomycin (P/S) were purchased from Fisher Scientific. The human recombinant cytokines, 
including M-CSF used for MDM differentiation was purchased from PeproTech (Rocky Hill, NJ), Recombinant 
Human IL-2 Protein was purchased from R&D system, Inc. (Minneapolis, MN). HIV-1 Ada strain was obtained 
from the NIH AIDS Reagent Program (Germantown, MD). RosetteSep enrichment cocktail was purchased from 
StemCell Technologies (Vancouver, Canada). The P24 ELISA kit (801111) was purchased from ZeptoMetrix Corp 
(Buffalo, NY) to assess HIV viral load in HIV-1-infected MDM.
All methods were carried out in accordance with relevant guidelines and regulations. All experimental pro-
tocols with cell lines and primary cells were approved by the Institutional Biosafety Committee (IBC) at the 
University of Tennessee Health Science (UTHSC). The protocols for analysis of blood samples from de-identified 
subjects obtained from Interstate Blood Bank (Memphis, TN) were approved by Institutional Review Board 
(IRB), UTHSC. The use of blood samples from de-identified subjects, bought from a blood bank, does not require 
informed consent from subjects and is waived from the IRB approval.
Preparation of PLGA-EVG/PLGA-C6 NPs. EVG loaded PLGA NPs were prepared by nano-precipitation 
technique as described in our previous report23. Cells were treated with 5 µg/mL of coumarin-6 equivalent PLGA 
nanoparticles at different Briefly, 45 mg of PLGA was dissolved in 4 mL of acetone (organic phase). EVG (4 mg) 
was added to the above organic phase, under constant magnetic stirring. The PLGA-EVG organic phase was 
then added dropwise into 10 mL of 1% PVA-aqueous solution on a magnetic stir plate at 400 rpm. After 3 hours, 
aqueous solution of 10 mg of PLL and 50 mg of F-68 were added to the nanoparticle suspension and stirred at 
room temperature to allow acetone evaporation. Finally, the larger aggregates were removed by centrifugation 
at 1000 rpm for 10 min. The finer and uniform PLGA-EVG NPs were stored at 4 °C/−20 °C for further study. 
Coumarin-6 (C6) loaded NPs were also prepared in a similar manner as EVG loaded PLGA NPs. C6 was used as a 
fluorescent model to track, locate, and measure the green fluorescence for semi-quantitative and qualitative cellu-
lar uptake. We have characterized both PLGA-EVG NPs and PLGA-C6 NPs in our previous report23. PLGA-EVG 
NPs and PLGA-C6 NPs showed similar particle sizes, and PLGA-C6 NPs were used to study subcellular localiza-
tion, cellular uptake and internalization, and BBB model transmigration in this study.
In vitro drug release. The in vitro drug release study was performed using a Float-A-Lyzer® dialysis device 
with molecular weight cut-off of 8–10 kDa (Sigma-Aldrich Co. Z726508). A volume of 1 mL PLGA-EVG NPs 
formulation was enclosed in a dialysis device and incubated in 30 mL cell culture media at 37 °C under mild 
agitation. At 15, 30 min, and 1, 3, 6, 9, 12, 24 h, 500 µL incubation media was withdrawn and analyzed for EVG 
level using LC-MS/MS. The same volume of fresh media was added to the incubation media after each sampling.
Human serum protein binding to PLGA NPs. Three hundred micrograms of PLGA NPs were incubated 
with 1–50% HS for 3 hours at 37 °C. The HS bound PLGA NPs were obtained by centrifugation of this NPs-HS 
mixed solution at 10,000 rpm for 20 min. The HS bound PLGA NPs60 in the pellet were denoted as % of HS@
NPs. For example, the 10% HS bound PLGA NPs were recognized as 10HS@NPs. To examine the HS protein 
adsorption on PLGA NPs, the HS@NPs samples were either resuspended in PBS for a dynamic light scatter-
ing (DLS) analysis or lyophilized using the Labconco Freeze Dry System (−53 °C, 133 × 10−3 mBar; Labconco, 
Kansas City, MO) to perform a Fourier Transform Infrared (FTIR) spectroscopy. The HS protein adsorption on 
PLGA NPs was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis 
as described61. Briefly, the adsorption capacity of HS proteins was studied based on 3 protocols: (1) equal amount 
(300 µg) of PLGA NPs were incubated with various concentration (1–50%) of HS for a fixed incubation period 
(3 h); (2) equal amount (300 µg) of PLGA NPs were incubated with a fixed concentration (10%) of HS for a var-
ious incubation period (0.5, 1, 2, 3 and 24 h); and (3) various amount (10–300 µg) of PLGA NPs were incubated 
with a fixed concentration (10%) of HS for a fixed incubation period (3 h). The HS@NPs were obtained by cen-
trifugation at 10,000 rpm for 20 min. The HS@NPs samples were separated by size in a 10% SDS-PAGE analysis 
using the constant voltage of 150 V for 75 min. The SDS-PAGE gel was processed for a Bio-Safe™ Coomassie Stain 
(BioRad, Hercules, CA), and scanned using a BioRad Gel Doc.
Dynamic light scattering. A DLS analysis was performed to measure the particle size and zeta potential of 
PLGA NPs or HS@NPs using a Zetasizer instrument (Nano ZS, Malvern Instruments Ltd., Worcestershire, UK). 
Both particle size and zeta potential of NPs/HS@NPs were measured in PBS at 25 °C. The particle size of each 
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sample was measured for 3 min (~15 runs), and the zeta potential of each sample was measured for 90 runs. The 
average particle size and zeta potential of 3 readings were calculated and reported for each sample.
Fourier transform infrared spectroscopy. FTIR spectroscopy was employed to confirm the extent of 
binding or presence of HS proteins on HS@NPs. The FTIR spectra of lyophilized HS@NPs were acquired using 
PerkinElmer Spectrum 100 FTIR spectrometer (Waltham, MA) equipped with a Diamond/ZnSe Attenuated Total 
Reflection crystal plate. PLGA NPs were used as a negative control, and the pure HS was used as a positive con-
trol. An average of 32 scans was performed on all the samples. The spectra were scanned from 4000 to 600 to cm−1 
with a resolution of 4 cm−1.
Stability assay. We determined the particle size and zeta potential of PLGA NPs using DLS. PLGA NPs 
were stored at room temperature, 4 °C, or −20 °C for a stability test. DLS analysis was performed on the room 
temperature sample for 7 days. The size and zeta potential of PLGA NPs from 4 °C and −20 °C were measured on 
day 7, and an additional measurement was performed on day 30 for the −20 °C sample. The particle size and zeta 
potential of PLGA NPs in 1 mM HEPES buffer from pH 1 to pH 11 were measured to investigate the alteration of 
PLGA NPs with this pH range.
Hemocompatibility. The red blood cells (RBCs) were collected from the de-identified human blood. The 
freshly collected RBCs were resuspended in RPMI phenol red free media for a hemolysis assay as described in 
our previous report61. Briefly, the RBC suspension (600 µL) was incubated with 5–200 µg/mL EVG or equivalent 
concentrations of PLGA-EVG, 30HS@PLGA-EVG, and PLGA-blank, 30HS@PLGA-blank in Eppendorf tubes 
for 3 hours at 37 °C. After incubation, the experimental tubes were centrifuged at 1000 rpm for 10 min and the 
supernatant was transferred to a 96-well plate to measure the release of hemoglobin using a plate reader (Cytation 
5 imaging, BioTek, Winooski, VT) at 570 nm. Ten microliter of RBCs from the pellet were imaged on a glass slide 
using the AMF4300 EVOS® FL Imaging System (Life Technologies, Carlsbad, CA). RBCs dissolved in MilliQ 
water was used as a positive control #1 (100% of hemolysis). SDS was used as positive control #2 (hemo-toxicity), 
and PBS was used as a negative control (0% of hemolysis) in this experiment.
Generation of HIV-1-infected primary macrophages. Peripheral blood mononuclear cells (PBMCs) 
was used to generate MDM according to previously published reports62,63. Briefly, the buffy coats were diluted 
and layered over the lymphocyte separation medium and centrifuged for 20 min at 1200 g. PBMCs for MDM 
differentiation were collected and cultured in RPMI media containing 10% HS, 1% L-glutamine, and 5% 
penicillin-streptomycin. After overnight incubation, non-adherent cells were washed by PBS. The adherent 
PBMCs were used for the generation of macrophages. M-CSF (50 ng/mL) was added to the MDM flasks for 
macrophage differentiation. For HIV-infection, mature MDM were collected after 7 days of differentiation, fol-
lowed by incubation with polybrene (2 µg/mL) and HIV-1 Ada strain (30 ng/1 × 106 cells) for HIV-1 infection in 
a 12-well plate with 3 × 105 cells/well. After overnight incubation, MDM were washed twice with PBS to remove 
the polybrene and HIV-1 Ada strain. The cells attached on the bottom of the well were considered as healthy 
primary MDM with initial HIV-1 infection. IL-2 (10 ng/mL) was added to the culture media of MDM to induce 
HIV-1 infection. After 7–10 days of the initial HIV-1 infection, cell culture media samples from MDM were 
collected to assess HIV-1 p24 level using a p24 ELISA kit (ZeptoMetrix Corp, Buffalo, NY) to confirm the HIV-1 
infection.
Cellular toxicity assay. Cellular toxicity assay was performed on MDM in the presence of EVG native drug, 
PLGA-EVG NPs, and HS30@PLGA-EVG using an XTT cell viability kit (Cell signaling, Danvers, MA). In this 
study, MDM were seeded into 96-well plates (2 × 104 in each well). Cells were incubated with 0–20 µM of EVG 
or equivalent concentrations of PLGA-EVG, and HS30@PLGA-EVG for 24 hours. The cells were washed twice 
with PBS and replaced with 100 µL fresh media. Subsequently, 50 µL of XTT detection solution, which contains 
electron coupling solution, was added to each well of the 96-well plate. MDM were incubated with XTT detection 
solution for 3 hours and absorbance was measured using a plate reader at 450 nm. The percentage of viable cells 
from treatment groups was calculated by comparing the absorbance with the untreated cells. Data presented are 
from five replicates.
Sub-cellular localization. In this study, PLGA-C6 NPs were used to visualize the sub-cellular localization 
of the NPs. MDM were seeded on 4-well cell culture chamber glass slides (CellTreat, Pepperell, MA). Cells were 
treated with 2.5 µg/mL of PLGA-C6 NPs for 2 hours. Subsequently, cells were incubated with markers for mito-
chondria (MitoTrackerTM Deep Red), early endosome (Texas RedTM Conjugate), late endosome (CellLightTM 
Late Endosomes-RFP), and lysosome (LysoTrackerR Red DND-99, Life Technologies) for 30 minutes. After the 
incubation, cells were fixed using 4% paraformaldehyde for 20 minutes and permeabilized with 0.2% TritonX-100 
for 5 minutes. All the cells were stained with DAPI (Life Technologies) and mounted in Vectashield Mounting 
Medium (Vector Labs, Burlingame, CA) to visualize nuclei. All the images were taken using a laser confocal 
microscope (Carl Zeiss LSM 710, Oberkochen, Germany) under 400 × magnification using oil immersion 
objective.
Cellular uptake and internalization mechanism. MDM were seeded in 6-well plates at a density of 8 × 
105 cells/well. The cells were pretreated with various endocytosis inhibitors for 30 min at 37 °C. The inhibitors were: 
nocodazole (10 µg/mL), Cyto-D (10 µg/mL), CPZ (10 µg/mL), monensin (200 nM), genistein (200 µM), and MβCD 
(1 mM). The cells were incubated with 2.5 µg/mL PLGA-C6 NPs for 2 hours at 37 °C. After the treatment, cells were 
washed twice with PBS, trypsinized, and collected to measure the cellular uptake. Semi-quantitative PLGA-C6 
uptake in MDM were measured using Accuri C6 Flow Cytometer (Accuri Cytometer Inc, Ann Arbor, MI). 
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Images were taken with a laser confocal microscope (Carl Zeiss LSM 710) under 400× magnification using oil 
immersion objective.
In vitro BBB model. Mouse brain endothelial cells bEnd.3 and mouse astrocytes C8-D1A were cultured in 
complete media (DMEM media with 10% fetal bovine serum and 1% penicillin-streptomycin solution) in T75 
flasks at 37 °C in a humidified incubator with 5% CO2 before building in vitro BBB model. Transwell® -COL 
collagen-coated 0.4 μm pore polytetrafluoroethylene membrane insert (Sigma-Aldrich) was used to build an 
in vitro BBB model as previous published protocols32,64. Mouse astrocytes were seeded on the bottom of 12-well 
plates at a density of 2 × 105 cells/well. After 24 hours of adhesion, mouse endothelial cells were seeded onto 
the upper side of the Transwell®- COL inserts at a density of 2 × 105 cells/well, and the inserts were placed in a 
12-well plate containing astrocytes. The in vitro BBB model was grown for 5 days to achieve ~90% confluency for 
transmigration assay.
Trans endothelial electrical resistance (TEER) measurements. The integrity of the tight junc-
tion dynamics of the BBB model was measured in terms of transendothelial electrical resistance (TEER) using 
EVOM2 Epithelial Voltohmmeter (World Precision Instruments, Sarasota, FL)65. TEER values were measured 
regularly every day for 6 days from the day of cell seeding. The TEER values were also measured during the exper-
iment period to assess the integrity of the endothelial cell layer. TEER of the blank insert with media alone was 
subtracted from the TEER final reading to obtain the TEER value for the endothelial monolayer. The TEER value 
was presented as the value of resistance (current, Ohm) multiplied by the area (cm2) of the endothelial monolayer 
(Ohm⋅cm2).
Transmigration study of PLGA NPs. The transmigration of PLGA NPs was visualized and measured 
using fluorescence dye C6 in a confluent in vitro BBB model. PLGA-C6 NPs at concentrations of 2.5, 5, and 
10 µg/mL were added to the upper inserts and incubated at 37 °C for 24 hours. After incubation, astrocytes in the 
bottom chamber were washed twice with PBS. The media of the bottom chamber was measured using a fluores-
cence plate reader (SpectraMAX M2e; Molecular Devices, San Jose, CA) with excitation at 488 nm and emission 
between 400 and 650 nm. The transmigration of PLGA-C6 NPs was presented in terms of fluorescence intensity. 
C6 concentration in the media was also calculated using a C6 calibration curve with the matrix of media. The 
images of receiving astrocytes were taken by EVOS® FL Imaging System.
Penetration of PLGA-EVG NPs in the in vitro BBB model. The in vitro BBB model was used to assess 
the penetration of the PLGA-EVG NPs. We performed a 24-hour EVG native drug/PLGA-EVG NPs treatment 
on the BBB cells. EVG native drug/PLGA-EVG NPs at concentrations of 2.5, 5, and 10 µg/mL were added to the 
upper inserts and incubated at 37 °C for 24 hours. A sample of 50 µL of receiver media was collected at 1, 3, 6, 9, 
and 24-hour time point, and an equal volume of fresh media was added. At the end of the experiment, the cells 
from the bottom chambers were collected in RIPA buffer as the cell lysate. The amount of EVG flux to the bottom 
chambers from both media and cell lysate was measured using our developed LC/MS method66.
Quantification of EVG using LC-MS/MS. A 50 µL of media or cell lysate samples were mixed with 
3-volumes of cold acetonitrile containing internal standard (IS) ritonavir (50 ng/mL). The mixed solution was 
vortexed and centrifuged at 8000 rpm for 10 min for protein precipitation. A clear supernatant was collected and 
analyzed using our established LC-MS/MS method66. Briefly, a Shimadzu liquid chromatographic system (Kyoto, 
Japan) coupled with an AB SCIEX Triple Quad 5500 tandem mass spectrometer (Framingham, MA) was used for 
the analysis. Chromatographic separation was performed on an Xterra® MS C18 column (125 Å, 3.5 μm, 4.6 mm 
× 50 mm; Waters, Milford, MA). The mobile phase used for EVG separation consisted of (A) water with 0.1% 
formic acid and (B) acetonitrile with 0.1% formic acid (v/v) at a flow rate of 1 mL/min. The gradient elution was 
as follows: 0–1.5 min, 50% B; 1.5–5.1 min, 60% B (v/v). The quantification of the validated assay of EVG was 1 
to 500 ng/mL. EVG and IS were eluted separately at approximately 3.27 and 2.72 min, respectively. The multiple 
reactions monitoring (MRM) transitions (m/z) Q1/Q3 selected for quantitative analyses were 447.9/343.8 for 
EVG and 721.3/296.1 for the IS. In order to reduce matrix effects, calibration curves were prepared with blank 
media or cell lysate based on the sample types.
Mechanistic contribution of P-gp in interfering the penetration of EVG in the in vitro BBB 
model. The mechanistic contribution of P-gp in interfering with the penetration of EVG was assessed in the 
presence and absence of the P-gp inhibitor elacridar. The in vitro BBB layer was preincubated with/without elac-
ridar (500 nM) for 30 min before the penetration study. After preincubation, 5 µg/mL of EVG native drug/PLGA 
EVG NPs were added to the upper inserts and incubated at 37 °C for 24 hours. A sample of 100 µL of media from 
the bottom chamber was collected at 1, 3, 6, 9, and 24-hour time point, and an equal volume of fresh media was 
added. The amount of EVG flux to the bottom chambers was measured using LC-MS/MS method.
Viral suppression of PLGA-EVG NPs in HIV-1-infected MDM after crossing in vitro BBB 
model. To determine the efficacy of the viral suppression of PLGA-EVG NPs, we used HIV-1-infected 
primary MDM to create a modified in vitro BBB model in a Transwell® plate. The confluent brain endothelial 
monolayer was obtained as described in the previous section. The upper insert of the in vitro BBB model con-
taining confluent brain endothelial cells was transferred to the 12-well plate containing HIV-1 infected MDM, 
and co-cultured with HIV-1-infected MDM. In this modified in vitro BBB model, HIV-1-infected MDM were 
cultured on the bottom of the 12-well plate. Endothelial monolayers in the upper inserts were exposed to control, 
blank PLGA NPs, EVG native drug (5 µg/mL), and PLGA-EVG NPs (5 µg/mL) for 7 days. HIV-1 viral loads were 
measured every day using a p24 ELISA kit from the culture media from the bottom chamber. The upper inserts 
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were replaced with fresh BBB cells after 3 days to keep BBB monolayer confluent. A mean TEER value of 100 to 
120 Ohms/cm2 that was obtained every day, was consistent with the modified BBB model during the time of the 
experiment. EVG levels in MDM were measured from the day-7 cell lysate samples at the end of the experiment 
using LC-MS/MS. All the HIV-1 related experiments were performed in the BSL-3 laboratory in the Regional 
Biocontainment Laboratory (RBL) of UTHSC.
Statistical analysis. All graphs and statistical analyses were performed using GraphPad Prism 5 (GraphPad 
Software; La Jolla, CA). Student’s t-test analysis was used for comparisons between two groups. The statistical 
significance among treatments was determined from one-way ANOVA post-hoc Tukey HSD Test. A p-value ≤ 
0.05 was considered significant.
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